{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:26:32Z","timestamp":1772166392298,"version":"3.50.1"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T00:00:00Z","timestamp":1766880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002749","name":"Belgian Federal Science Policy Office","doi-asserted-by":"publisher","award":["B2\/202\/P3\/HELICON"],"award-info":[{"award-number":["B2\/202\/P3\/HELICON"]}],"id":[{"id":"10.13039\/501100002749","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-025-02207-2","type":"journal-article","created":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T15:03:46Z","timestamp":1766934226000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Subtype-specific health and economic impact of delayed breast cancer diagnosis during the early COVID-19 pandemic in Belgium: a Markov model analysis"],"prefix":"10.1186","volume":"28","author":[{"given":"Yasmine","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Verhaeghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Monten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrien","family":"Vanthomme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Gadeyne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brecht","family":"Devleesschauwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Freija","family":"Verdoodt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna M.","family":"Peacock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"De Smedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,28]]},"reference":[{"key":"2207_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejca.2020.01.011","volume":"129","author":"T Hofmarcher","year":"2020","unstructured":"Hofmarcher T, Lindgren P, Wilking N, J\u00f6nsson B. The cost of cancer in Europe 2018. Eur J Cancer. 2020;129:41\u20139.","journal-title":"Eur J Cancer"},{"key":"2207_CR2","unstructured":"JRC. Cancer care in times of COVID-19: lessons for future pandemics. 2023; Disponible sur: https:\/\/joint-research-centre.ec.europa.eu\/jrc-news-and-updates\/cancer-care-times-covid-19-lessons-future-pandemics-2023-02-28_en"},{"key":"2207_CR3","unstructured":"WHO. Cancer. 2022; Disponible sur: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer"},{"issue":"3","key":"2207_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6659","volume":"13","author":"V Gorasso","year":"2024","unstructured":"Gorasso V, Vandevijvere S, Van der Heyden J, Pelgrims I, Hilderink H, Nusselder W, et al. The incremental healthcare cost associated with cancer in Belgium: a registry\u2010based data analysis. Cancer Med. 2024;13(3):e6659.","journal-title":"Cancer Med"},{"issue":"5","key":"2207_CR5","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.3390\/curroncol29050287","volume":"29","author":"P Hanly","year":"2022","unstructured":"Hanly P, Ortega-Ortega M, Soerjomataram I. Cancer premature mortality costs in Europe in 2020: a comparison of the human capital approach and the friction cost approach. Curr Oncol. 2022;29(5):3552\u201364.","journal-title":"Curr Oncol"},{"key":"2207_CR6","unstructured":"IARC. Cancer today - Age-Standardized Rate (World) per 100 000, Incidence and Mortality, Both sexes, in 2022 [Internet]. 2024. Disponible sur: https:\/\/gco.iarc.who.int\/today\/en\/dataviz\/bars?mode=population%26;group_populations=0%26;types=0_1%26;sort_by=value1%26;cancers=20%26;populations=%26;nb_items=-1%26;sexes=2"},{"key":"2207_CR7","unstructured":"AIHTA. Oncological Breast Cancer Care in Selected European Countries. 2024; Disponible sur: https:\/\/eprints.aihta.at\/1545\/1\/HTA-Projektbericht_Nr.162.pdf"},{"key":"2207_CR8","unstructured":"WHO. Overview of Public Health and Social Measures in the context of COVID-19 [Internet]. 2020 [cit\u00e9 2 juill 2025]. Disponible sur: https:\/\/www.who.int\/publications\/i\/item\/overview-of-public-health-and-social-measures-in-the-context-of-covid-19"},{"key":"2207_CR9","unstructured":"World Health Organization. Pulse survey on continuity of essential health services during the COVID-19 pandemic: interim report, 27 August 2020. 2020 [cit\u00e9 24 avr 2025]; Disponible sur: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-EHS_continuity-survey-2020.1"},{"issue":"3 Suppl","key":"2207_CR10","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.21873\/invivo.11957","volume":"34","author":"G Vanni","year":"2020","unstructured":"Vanni G, Materazzo M, Pellicciaro M, Ingallinella S, Rho M, Santori F, et al. Breast cancer and COVID-19: the effect of fear on patients\u2019 decision-making process. In Vivo. 2020;34(3 Suppl):1651.","journal-title":"In Vivo"},{"issue":"13","key":"2207_CR11","doi-asserted-by":"publisher","first-page":"4502","DOI":"10.3390\/jcm12134502","volume":"12","author":"H Abdel-Razeq","year":"2023","unstructured":"Abdel-Razeq H, Mansour A, Edaily S, Dayyat A. Delays in initiating anti-cancer therapy for early-stage breast cancer\u2014how slow can we Go? J Clin Med. 2023;12(13):4502.","journal-title":"J Clin Med"},{"key":"2207_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3389\/fpubh.2014.00087","volume":"2","author":"L Caplan","year":"2014","unstructured":"Caplan L. Delay in breast cancer: implications for stage at diagnosis and survival. Front Public Health. 2014;2:87.","journal-title":"Front Public Health"},{"key":"2207_CR13","doi-asserted-by":"publisher","first-page":"m4087","DOI":"10.1136\/bmj.m4087","volume":"371","author":"TP Hanna","year":"2020","unstructured":"Hanna TP, King WD, Thibodeau S, Jalink M, Paulin GA, Harvey-Jones E, et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ. 2020;371:m4087.","journal-title":"BMJ"},{"key":"2207_CR14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13690-024-01296-3","volume":"82","author":"HM Peacock","year":"2024","unstructured":"Peacock HM, van Walle L, Silversmit G, Neven P, Han SN, Van Damme N. Breast cancer incidence, stage distribution, and treatment shifts during the 2020 COVID-19 pandemic: a nationwide population-level study. Arch Public Health. 2024;82:66.","journal-title":"Arch Public Health."},{"key":"2207_CR15","unstructured":"ESMO. ESMO Clinical Practice Guideline: Early Breast Cancer [Internet]. 2024 [cit\u00e9 4 juill 2025]. Disponible sur: https:\/\/www.esmo.org\/guidelines\/esmo-clinical-practice-guideline-early-breast-cancer"},{"issue":"12","key":"2207_CR16","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, Cort\u00e9s J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer\u2606. Ann Oncol. 2021;32(12):1475\u201395.","journal-title":"Ann Oncol"},{"key":"2207_CR17","doi-asserted-by":"crossref","unstructured":"Orrantia-Borunda E, Anchondo-Nu\u00f1ez P, Acu\u00f1a-Aguilar LE, G\u00f3mez-Valles FO, Ram\u00edrez-Valdespino CA. Subtypes of Breast Cancer. In: Mayrovitz HN, \u00e9diteur. Breast Cancer [Internet]. Brisbane (AU): Exon Publications; 2022 [cit\u00e9 25 janv 2025]. Disponible sur: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK583808\/","DOI":"10.36255\/exon-publications-breast-cancer-subtypes"},{"key":"2207_CR18","unstructured":"van\u00a0Walle L. Incidence of breast cancer subtypes in Belgium: a population-based study. BJMO [Internet]. 2020 [cit\u00e9 16 avr 2025]; Disponible sur: https:\/\/www.bjmo.be\/journal-article\/incidence-of-breast-cancer-subtypes-in-belgium-a-population-based-study\/"},{"key":"2207_CR19","doi-asserted-by":"publisher","first-page":"e2200289","DOI":"10.1200\/GO.22.00289","volume":"8","author":"CAA Resende","year":"2022","unstructured":"Resende CAA, Fernandes Cruz HM, Costa e Silva M, Paes RD, Dienstmann R, Barrios CHE, et al. Impact of the COVID-19 pandemic on cancer staging: an analysis of patients with breast cancer from a community practice in Brazil. JCO Glob Oncol. 2022;8:e2200289.","journal-title":"JCO Glob Oncol."},{"issue":"8","key":"2207_CR20","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1470-2045(20)30388-0","volume":"21","author":"C Maringe","year":"2020","unstructured":"Maringe C, Spicer J, Morris M, Purushotham A, Nolte E, Sullivan R, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol ao\u00fbt. 2020;21(8):1023\u201334.","journal-title":"Lancet Oncol ao\u00fbt"},{"issue":"11","key":"2207_CR21","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1093\/jnci\/djab097","volume":"113","author":"O Alagoz","year":"2021","unstructured":"Alagoz O, Lowry KP, Kurian AW, Mandelblatt JS, Ergun MA, Huang H, et al. Impact of the COVID-19 pandemic on breast cancer mortality in the US: estimates from collaborative simulation modeling. JNCI J Natl Cancer Inst. 2021;113(11):1484\u201394.","journal-title":"JNCI J Natl Cancer Inst."},{"issue":"2","key":"2207_CR22","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1177\/0969141320974711","volume":"28","author":"JH Yong","year":"2021","unstructured":"Yong JH, Mainprize JG, Yaffe MJ, Ruan Y, Poirier AE, Coldman A, et al. The impact of episodic screening interruption: COVID-19 and population-based cancer screening in Canada. J Med Screen juin. 2021;28(2):100\u20137.","journal-title":"J Med Screen juin"},{"key":"2207_CR23","doi-asserted-by":"crossref","unstructured":"Dul M, Grzeszczyk MK, Nojszewska E, Sitek A. Estimation of the Impact of COVID-19 Pandemic Lockdowns on Breast Cancer Deaths and Costs in Poland using Markovian Monte Carlo Simulation [Internet]. arXiv; 2023 [cit\u00e9 4 d\u00e9c 2024]. Disponible sur: http:\/\/arxiv.org\/abs\/2305.00908","DOI":"10.1007\/978-3-031-36024-4_10"},{"key":"2207_CR24","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.ejca.2021.04.019","volume":"152","author":"A Gheorghe","year":"2021","unstructured":"Gheorghe A, Maringe C, Spice J, Purushotham A, Chalkidou K, Rachet B, et al. Economic impact of avoidable cancer deaths caused by diagnostic delay during the COVID-19 pandemic: A national population-based modelling study in England, UK. Eur J Cancer. 2021;152:233\u201342.","journal-title":"Eur J Cancer"},{"key":"2207_CR25","doi-asserted-by":"crossref","unstructured":"Alsalamah RA, Alsalamah DRA. Critical Diagnostic Delay Thresholds in Breast Cancer: A Molecular Subtype-Based Causal Analysis From Saudi Arabia. Cureus [Internet]. 24 mars 2025 [cit\u00e9 29 mars 2025];17(3). Disponible sur: https:\/\/www.cureus.com\/articles\/351382-critical-diagnostic-delay-thresholds-in-breast-cancer-a-molecular-subtype-based-causal-analysis-from-saudi-arabia","DOI":"10.7759\/cureus.81106"},{"key":"2207_CR26","unstructured":"KCE. BELGIAN GUIDELINES FOR ECONOMIC EVALUATIONS AND BUDGET IMPACT ANALYSES: THIRD EDITION [Internet]. 2025. Disponible sur: https:\/\/kce.fgov.be\/sites\/default\/files\/2025-05\/KCE400_Method_guidelines_economic_evaluations.pdf"},{"issue":"2","key":"2207_CR27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/ijc.31914","volume":"144","author":"MC van Maaren","year":"2019","unstructured":"van Maaren MC, de Munck L, Strobbe LJA, Sonke GS, Westenend PJ, Smidt ML, et al. Ten-year recurrence rates for breast cancer subtypes in the Netherlands: a large population-based study. Int J Cancer. 2019;144(2):263\u201372.","journal-title":"Int J Cancer"},{"issue":"10","key":"2207_CR28","doi-asserted-by":"publisher","first-page":"e0288777","DOI":"10.1371\/journal.pone.0288777","volume":"18","author":"Y Khan","year":"2023","unstructured":"Khan Y, Verhaeghe N, Pauw RD, Devleesschauwer B, Gadeyne S, Gorasso V, et al. Evaluating the health and health economic impact of the COVID-19 pandemic on delayed cancer care in Belgium: a Markov model study protocol. PLoS ONE. 2023;18(10):e0288777.","journal-title":"PLoS ONE"},{"issue":"4","key":"2207_CR29","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1177\/0272989X9301300409","volume":"13","author":"FA Sonnenberg","year":"1993","unstructured":"Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13(4):322\u201338.","journal-title":"Med Decis Making"},{"key":"2207_CR30","unstructured":"Belgian Cancer Registry. Mission. 2024; Disponible sur: https:\/\/kankerregister.org\/en\/mission"},{"key":"2207_CR31","doi-asserted-by":"crossref","unstructured":"Lobo-Martins S, Arecco L, Cabral TP, Agostinetto E, Dauccia C, Franzoi MA, et al. Extended adjuvant endocrine therapy in early breast cancer: finding the individual balance. ESMO Open [Internet]. 1 mai 2025 [cit\u00e9 8 juill 2025];10(5). Disponible sur: https:\/\/www.esmoopen.com\/article\/S2059-7029(25)00926-3\/fulltext","DOI":"10.1016\/j.esmoop.2025.105057"},{"issue":"8","key":"2207_CR32","doi-asserted-by":"publisher","first-page":"4489","DOI":"10.1007\/s00432-022-04245-1","volume":"149","author":"T Intrieri","year":"2022","unstructured":"Intrieri T, Manneschi G, Caldarella A. 10-year survival in female breast cancer patients according to ER, PR and HER2 expression: a cancer registry population-based analysis. J Cancer Res Clin Oncol. 2022;149(8):4489\u201396.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2207_CR33","unstructured":"RIVIZ. Nomensoft: Nomenclatuur en pseudonomenclatuur van de geneeskundige verstrekkingen [Internet]. 2025. Disponible sur: https:\/\/webappsa.riziv-inami.fgov.be\/Nomen\/fr\/search"},{"key":"2207_CR34","unstructured":"BCFI. Belgisch Centrum voor Farmacotherapeutische Informatie [Internet]. 2025. Disponible sur: https:\/\/www.bcfi.be\/nl\/"},{"key":"2207_CR35","unstructured":"Statbel. Health Index. 2025; Disponible sur: https:\/\/statbel.fgov.be\/en\/themes\/consumer-prices\/health-index"},{"issue":"2","key":"2207_CR36","first-page":"527","volume":"31","author":"L Van Wilder","year":"2022","unstructured":"Van Wilder L, Charafeddine R, Beutels P, Bruyndonckx R, Cleemput I, Demarest S, et al. Belgian population norms for the EQ-5D-5L, 2018. Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2022;31(2):527\u201337.","journal-title":"Qual Life Res Int J Qual Life Asp Treat Care Rehabil."},{"issue":"1","key":"2207_CR37","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/ijc.34899","volume":"155","author":"LM Kregting","year":"2024","unstructured":"Kregting LM, Vrancken Peeters NJMC, Clarijs ME, Koppert LB, Korfage IJ, van Ravesteyn NT. Health utility values of breast cancer treatments and the impact of varying quality of life assumptions on cost-effectiveness. Int J Cancer. 2024;155(1):117\u201327.","journal-title":"Int J Cancer"},{"issue":"8","key":"2207_CR38","doi-asserted-by":"publisher","first-page":"e0307225","DOI":"10.1371\/journal.pone.0307225","volume":"19","author":"S Torres","year":"2024","unstructured":"Torres S, Bayoumi AM, Abrahao ABK, Trudeau M, Pritchard KI, Li CN, et al. Implementing routine collection of EQ-5D-5L in a breast cancer outpatient clinic. PLoS ONE. 2024;19(8):e0307225.","journal-title":"PLoS ONE"},{"key":"2207_CR39","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.breast.2019.04.006","volume":"46","author":"DHM Jacobs","year":"2019","unstructured":"Jacobs DHM, Horeweg N, Straver M, Roeloffzen EMA, Speijer G, Merkus J, et al. Health-related quality of life of breast cancer patients after accelerated partial breast irradiation using intraoperative or external beam radiotherapy technique. The Breast. 2019;46:32\u20139.","journal-title":"The Breast"},{"issue":"1","key":"2207_CR40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.clon.2014.09.007","volume":"27","author":"P Sundaresan","year":"2015","unstructured":"Sundaresan P, Sullivan L, Pendlebury S, Kirby A, Rodger A, Joseph D, et al. Patients\u2019 perceptions of health-related quality of life during and after adjuvant radiotherapy for T1N0M0 breast cancer. Clin Oncol. 2015;27(1):9\u201315.","journal-title":"Clin Oncol"},{"key":"2207_CR41","doi-asserted-by":"publisher","first-page":"1090326","DOI":"10.3389\/fphar.2023.1090326","volume":"14","author":"SM Khoirunnisa","year":"2023","unstructured":"Khoirunnisa SM, Suryanegara FDA, Setiawan D, Postma MJ. Health-related quality of life in Her2-positive early breast cancer woman using trastuzumab: a systematic review and meta-analysis. Front Pharmacol. 2023;14:1090326.","journal-title":"Front Pharmacol"},{"issue":"4","key":"2207_CR42","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3816\/CBC.2010.n.037","volume":"10","author":"H Rugo","year":"2010","unstructured":"Rugo H, Brammer M, Zhang F, Lalla D. Effect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: data from three clinical trials. Clin Breast Cancer. 2010;10(4):288\u201393.","journal-title":"Clin Breast Cancer"},{"issue":"11","key":"2207_CR43","doi-asserted-by":"publisher","first-page":"e061967","DOI":"10.1136\/bmjopen-2022-061967","volume":"12","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Chen L, Zheng X, Shi Y. Quality of life in patients with breast cancer with neoadjuvant chemotherapy: a systematic review. BMJ Open. 2022;12(11):e061967.","journal-title":"BMJ Open"},{"key":"2207_CR44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e23167","author":"M Liu","year":"2024","unstructured":"Liu M, Goldberg J, Norton L, Robson ME, Zhi I. Immunotherapy related patient-reported outcomes from five randomized controlled trials in patients with triple negative breast cancer: a systematic review. J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.e23167.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2207_CR45","first-page":"1073","volume":"16","author":"M Lidgren","year":"2007","unstructured":"Lidgren M, Wilking N, J\u00f6nsson B, Rehnberg C. Health related quality of life in different states of breast cancer. Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2007;16(6):1073\u201381.","journal-title":"Qual Life Res Int J Qual Life Asp Treat Care Rehabil."},{"issue":"2","key":"2207_CR46","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40259-019-00337-6","volume":"33","author":"TK Eggersmann","year":"2019","unstructured":"Eggersmann TK, Degenhardt T, Gluz O, Wuerstlein R, Harbeck N. CDK4\/6 inhibitors expand the therapeutic options in breast cancer: palbociclib. Ribociclib Abemaciclib BioDrugs. 2019;33(2):125\u201335.","journal-title":"Ribociclib Abemaciclib BioDrugs."},{"key":"2207_CR47","unstructured":"Mason SR, Willson ML, Egger SJ, Beith J, Dear RF, Goodwin A. Platinum chemotherapy for early triple-negative breast cancer. The Breast [Internet]. 1 juin 2024 [cit\u00e9 29 mars 2025];75. Disponible sur: https:\/\/www.thebreastonline.com\/article\/S0960-9776(24)00043-2\/fulltext#fig3"},{"issue":"30","key":"2207_CR48","doi-asserted-by":"publisher","first-page":"4594","DOI":"10.1200\/JCO.2010.28.8415","volume":"28","author":"A Di Leo","year":"2010","unstructured":"Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, et al. Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg with Fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28(30):4594\u2013600.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2207_CR49","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s10549-020-05577-7","volume":"180","author":"N Paracha","year":"2020","unstructured":"Paracha N, Reyes A, Di\u00e9ras V, Krop I, Pivot X, Urruticoechea A. Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane\/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis. Breast Cancer Res Treat. 2020;180(3):597\u2013609.","journal-title":"Breast Cancer Res Treat"},{"issue":"16","key":"2207_CR50","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384(16):1529\u201341.","journal-title":"N Engl J Med"},{"key":"2207_CR51","doi-asserted-by":"crossref","unstructured":"Hurvitz SA, Kim SB, Chung WP, Im SA, Park YH, Hegg R, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial. ESMO Open [Internet]. 1 mai 2024 [cit\u00e9 29 mars 2025];9(5). Disponible sur: https:\/\/www.esmoopen.com\/article\/S2059-7029%2824%2900692-6\/fulltext","DOI":"10.1016\/j.esmoop.2024.102924"},{"issue":"3","key":"2207_CR52","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10549-015-3633-7","volume":"154","author":"J Cortes","year":"2015","unstructured":"Cortes J, Hudgens S, Twelves C, Perez EA, Awada A, Yelle L, et al. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Res Treat d\u00e9c. 2015;154(3):509\u201320.","journal-title":"Breast Cancer Res Treat d\u00e9c"},{"issue":"1","key":"2207_CR53","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9\u201320.","journal-title":"N Engl J Med"},{"issue":"153","key":"2207_CR54","first-page":"223","volume":"2021","author":"V Mueller","year":"1990","unstructured":"Mueller V, Wardley A, Paplomata E, Hamilton E, Zelnak A, Fehrenbacher L, et al. Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB\u00a0trial). Eur J Cancer Oxf Engl. 1990;2021(153):223\u201333.","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"10","key":"2207_CR55","doi-asserted-by":"publisher","first-page":"FSO750","DOI":"10.2144\/fsoa-2020-0095","volume":"7","author":"MR Valerio","year":"2021","unstructured":"Valerio MR, Spadaro P, Arcan\u00e0 C, Borsellino N, Cipolla C, Vigneri P, et al. Oral vinorelbine and capecitabine as first-line therapy in metastatic breast cancer: a retrospective analysis. Future Sci OA. 2021;7(10):FSO750.","journal-title":"Future Sci OA."},{"issue":"3","key":"2207_CR56","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/jnci\/djab202","volume":"114","author":"RN Pedersen","year":"2022","unstructured":"Pedersen RN, Esen B\u00d6, Mellemkj\u00e6r L, Christiansen P, Ejlertsen B, Lash TL, et al. The incidence of breast cancer recurrence 10\u201332 years after primary diagnosis. J Natl Cancer Inst. 2022;114(3):391\u20139.","journal-title":"J Natl Cancer Inst"},{"issue":"4_Supplement","key":"2207_CR57","doi-asserted-by":"publisher","first-page":"P4-7-25","DOI":"10.1158\/1538-7445.SABCS21-P4-07-25","volume":"82","author":"H Tokisawa","year":"2022","unstructured":"Tokisawa H, Aruga T, Honda Y, Ishiba T, Yonekura R, Iwamoto N, et al. Abstract P4\u201307\u201325: Distant metastasis of breast cancer is triggered by changes in the dynamics of metastatic cells after removal of the primary lesion. Cancer Res. 2022;82(4_Supplement):P4-7\u201325.","journal-title":"Cancer Res"},{"key":"2207_CR58","unstructured":"RIZIV. Verkorte bestraling bij borstkankerpati\u00ebnten tijdens de COVID-19-pandemie [Internet]. 2020. Disponible sur: https:\/\/www.riziv.fgov.be\/nl\/thema-s\/covid-19\/verkorte-bestraling-bij-borstkankerpatienten-tijdens-de-covid-19-pandemie"},{"issue":"1","key":"2207_CR59","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12955-024-02294-3","volume":"22","author":"S Bourke","year":"2024","unstructured":"Bourke S, Bennett B, Oluboyede Y, Li T, Longworth L, O\u2019Sullivan SB, et al. Estimating the minimally important difference for the EQ-5D-5L and EORTC QLQ-C30 in cancer. Health Qual Life Outcomes. 2024;22(1):81.","journal-title":"Health Qual Life Outcomes"},{"key":"2207_CR60","doi-asserted-by":"crossref","unstructured":"Sim\u00e3o D, Sardinha M, Reis AF, Spencer AS, Luz R, Oliveira S, et al. What Has Changed During the COVID-19 Pandemic? - The Effect on an Academic Breast Department in Portugal. Eur J Breast Health [Internet]. 30 d\u00e9c 2021 [cit\u00e9 22 ao\u00fbt 2025]; Disponible sur: https:\/\/eurjbreasthealth.com\/articles\/what-has-changed-during-the-covid-19-pandemic-the-effect-on-an-academic-breast-department-in-portugal\/ejbh.galenos.2021.2021-11-1","DOI":"10.4274\/ejbh.galenos.2021.2021-11-1"},{"key":"2207_CR61","unstructured":"European Federation of Pharmaceutical Industries and Associations. The impact of COVID-19 on patient access to cancer care in Europe [Internet]. 2021. Disponible sur: https:\/\/www.efpia.eu\/media\/602636\/every-day-counts-covid19-addendum.pdf"},{"key":"2207_CR62","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35001","author":"HM Peacock","year":"2024","unstructured":"Peacock HM, Van Meensel M, Van Gool B, Silversmit G, Dekoninck K, Brierley JD, et al. Cancer incidence, stage shift and survival during the 2020 COVID-19 pandemic: a population-based study in Belgium. Int J Cancer. 2024. https:\/\/doi.org\/10.1002\/ijc.35001.","journal-title":"Int J Cancer"},{"key":"2207_CR63","unstructured":"Konusevska A. European Cancer Organisation. 2024 [cit\u00e9 22 ao\u00fbt 2025]. The Time to Act is Now. Action Report from Covid-19 & Cancer Workforce Special Network Meeting. Disponible sur: https:\/\/www.europeancancer.org\/resources\/publications\/reports\/the-time-to-act-is-now-action-report.html"},{"key":"2207_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100197","author":"HM Peacock","year":"2021","unstructured":"Peacock HM, Tambuyzer T, Verdoodt F, Calay F, Poirel HA, Schutter HD, et al. Decline and incomplete recovery in cancer diagnoses during the COVID-19 pandemic in Belgium: a year-long, population-level analysis. ESMO Open. 2021. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100197.","journal-title":"ESMO Open"},{"issue":"1","key":"2207_CR65","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/eurpub\/ckae206","volume":"35","author":"A Gottlob","year":"2025","unstructured":"Gottlob A, Schmitt T, Frydensberg MS, Rosi\u0144ska M, Leclercq V, Habimana K. Telemedicine in cancer care: lessons from COVID-19 and solutions for Europe. Eur J Public Health. 2025;35(1):35\u201341.","journal-title":"Eur J Public Health"},{"issue":"8","key":"2207_CR66","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/S1470-2045(20)30392-2","volume":"21","author":"A Sud","year":"2020","unstructured":"Sud A, Torr B, Jones ME, Broggio J, Scott S, Loveday C, et al. Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study. Lancet Oncol. 2020;21(8):1035\u201344.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2207_CR67","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/ajco.13505","volume":"17","author":"K Degeling","year":"2021","unstructured":"Degeling K, Baxter NN, Emery J, Jenkins MA, Franchini F, Gibbs P, et al. An inverse stage-shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID-19 pandemic. Asia Pac J Clin Oncol. 2021;17(4):359\u201367.","journal-title":"Asia Pac J Clin Oncol"},{"key":"2207_CR68","unstructured":"OECD. Belgium: Country Health Profile 2023 [Internet]. 2023. Disponible sur: https:\/\/www.oecd.org\/content\/dam\/oecd\/en\/publications\/reports\/2023\/12\/belgium-country-health-profile-2023_01d0f3f9\/dd6df7bd-en.pdf"},{"key":"2207_CR69","unstructured":"INAMI. Remboursement des consultations m\u00e9dicales \u00e0 distance [Internet]. 2020. Disponible sur: https:\/\/www.inami.fgov.be\/fr\/themes\/soins-de-sante-cout-et-remboursement\/les-prestations-de-sante-que-vous-rembourse-votre-mutualite\/consultations-medicales-a-distance"},{"key":"2207_CR70","unstructured":"ESMO. ESMO management and treatment adapted recommendations in the COVID-19 era: Breast cancer [Internet]. 2020. Disponible sur: https:\/\/dam.esmo.org\/image\/upload\/v1755611032\/ESMO-guidelines-COVID19-breast-cancer-2020-04-15_cyxwsi.pdf"},{"key":"2207_CR71","unstructured":"NHS Wales. Breast Test Wales - Annual Statistical Report - 2020\u20132021 [Internet]. 2024. Disponible sur: https:\/\/phw.nhs.wales\/publications\/publications1\/breast-test-wales-annual-report-202021\/"},{"key":"2207_CR72","unstructured":"Scottish Government. Breast Cancer Screening to resume [Internet]. 2020. Disponible sur: https:\/\/www.gov.scot\/news\/breast-cancer-screening-to-resume\/"},{"issue":"19","key":"2207_CR73","doi-asserted-by":"publisher","first-page":"12456","DOI":"10.3390\/ijerph191912456","volume":"19","author":"I Kenis","year":"2022","unstructured":"Kenis I, Theys S, Hermie E, Foulon V, Van Hecke A. Impact of COVID-19 on the organization of cancer care in Belgium: lessons learned for the (post-)pandemic future. Int J Environ Res Public Health. 2022;19(19):12456.","journal-title":"Int J Environ Res Public Health"},{"key":"2207_CR74","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.77434","volume":"11","author":"G Bosch","year":"2022","unstructured":"Bosch G, Posso M, Louro J, Roman M, Porta M, Castells X, et al. Impact of the COVID-19 pandemic on breast cancer screening indicators in a Spanish population-based program: a cohort study. Elife. 2022;11:e77434.","journal-title":"Elife"},{"issue":"9","key":"2207_CR75","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1158\/1055-9965.EPI-15-0060","volume":"24","author":"A Bolejko","year":"2015","unstructured":"Bolejko A, Hagell P, Wann-Hansson C, Zackrisson S. Prevalence, long-term development, and predictors of psychosocial consequences of false-positive mammography among women attending population-based screening. Cancer Epidemiol Biomarkers Prev. 2015;24(9):1388\u201397.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"8","key":"2207_CR76","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1002\/ijc.33884","volume":"150","author":"T Malag\u00f3n","year":"2022","unstructured":"Malag\u00f3n T, Yong JHE, Tope P, Miller WHJr, Franco EL, McGill Task Force on the Impact of COVID-19 on Cancer Control and Care. Predicted long-term impact of COVID-19 pandemic-related care delays on cancer mortality in Canada. Int J Cancer. 2022;150(8):1244\u201354.","journal-title":"Int J Cancer"},{"key":"2207_CR77","doi-asserted-by":"publisher","first-page":"103020","DOI":"10.1016\/j.pmedr.2025.103020","volume":"52","author":"M Zhang","year":"2025","unstructured":"Zhang M, Tierney P, Brennan A, Murray D, Mullooly M, Bennett K. Modelling the impact of the COVID-19 pandemic on cancer stage migration and excess mortality in Ireland. Prev Med Rep. 2025;52:103020.","journal-title":"Prev Med Rep."},{"key":"2207_CR78","doi-asserted-by":"publisher","unstructured":"Figueroa JD, Gray E, Maeda Y, Hall PS, Mackean M, Elder K, et al. Modelling the Long-Term Effects of Covid-19 Cancer Services Disruption on Patient Outcome in Scotland [Internet]. medRxiv; 2021 [cit\u00e9 26 ao\u00fbt 2025]. p. 2021.01.17.21249993. Disponible sur: https:\/\/www.medrxiv.org\/content\/https:\/\/doi.org\/10.1101\/2021.01.17.21249993v1","DOI":"10.1101\/2021.01.17.21249993v1"},{"key":"2207_CR79","unstructured":"service public federal securite sociale. Arr\u00eat\u00e9 Royal du 13\/05\/2020 arrete royal n\u00b0 20 portant des mesures temporaires dans la lutte contre la pandemie covid-19 et visant a assurer la continuite des soins en matiere d\u2019assurance obligatoire soins de sante [Internet]. Moniteur Belge; 2020 mai [cit\u00e9 11 juill 2025]. Disponible sur: https:\/\/etaamb.openjustice.be\/fr\/arrete-royal-du-13-mai-2020_n2020041295"},{"issue":"20","key":"2207_CR80","doi-asserted-by":"publisher","first-page":"7560","DOI":"10.3390\/ijerph17207560","volume":"17","author":"C Faes","year":"2020","unstructured":"Faes C, Abrams S, Van Beckhoven D, Meyfroidt G, Vlieghe E, Hens N, et al. Time between symptom onset, hospitalisation and recovery or death: statistical analysis of Belgian COVID-19 patients. Int J Environ Res Public Health. 2020;17(20):7560.","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"2207_CR81","doi-asserted-by":"publisher","first-page":"12587","DOI":"10.1038\/s41598-017-12949-5","volume":"7","author":"JH Mao","year":"2017","unstructured":"Mao JH, van Diest PJ, Perez-Losada J, Snijders AM. Revisiting the impact of age and molecular subtype on overall survival after radiotherapy in breast cancer patients. Sci Rep. 2017;7(1):12587.","journal-title":"Sci Rep"},{"issue":"15_suppl","key":"2207_CR82","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1200\/JCO.2021.39.15_suppl.543","volume":"39","author":"K Allen","year":"2021","unstructured":"Allen K, Lohrisch CA, Le D, Diocee RM, Speers C, Nichol A, et al. Survival following locoregional recurrence in breast cancer by clinical subtype. J Clin Oncol. 2021;39(15_suppl):543\u2013543.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2207_CR83","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1055\/a-2286-5372","volume":"84","author":"AD Hartkopf","year":"2024","unstructured":"Hartkopf AD, Walter CB, Kolberg HC, Hadji P, Tesch H, Fasching PA, et al. Attrition in the first three therapy lines in patients with advanced breast cancer in the German real-world PRAEGNANT registry. Geburtshilfe Frauenheilkd mai. 2024;84(5):459\u201369.","journal-title":"Geburtshilfe Frauenheilkd mai"},{"issue":"22","key":"2207_CR84","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O\u2019Shaughnessy JA, et al. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med. 2024;391(22):2110\u201322.","journal-title":"N Engl J Med"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-025-02207-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02207-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02207-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T15:07:19Z","timestamp":1770649639000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-025-02207-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,28]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2207"],"URL":"https:\/\/doi.org\/10.1186\/s13058-025-02207-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7786399\/v1","asserted-by":"object"}]},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,28]]},"assertion":[{"value":"5 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was based on aggregated, de-identified registry data from the Belgian Cancer Registry (BCR), which exempted it from ethical review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}